Workflows to bridge that gap between discovery and clinical research
Focusing on oncology applications in lung and ovarian cancer, this session explored workflows utilizing plasma proteomics to better understand the relationship between responders and non-responders, research on chemotherapeutic resistance, and the identification of biomarkers for improve health outcomes. These innovative approaches are enhancing our ability to translate discoveries into clinical research, providing deeper insights into treatment efficacy and resistance mechanisms.
Learning points:
- How to build an end-to-end plasma proteomics workflow for translational oncology broad discovery → targeted validation with orthogonal assays, pre-analytical QC, and cohort design that scales to clinical studies.
- How proteomic signatures can differentiate responders vs. non-responders and reveal chemotherapy resistance mechanisms using longitudinal sampling and statistical modeling.
- How to turn candidate biomarkers into clinically useful readouts setting cutoffs, validating across independent cohorts, and integrating results with clinical covariates to support trial/CLIA translation.
Who should attend:
- Translational oncology researchers & clinicians focused on lung or ovarian cancer who are evaluating treatment efficacy, patient stratification, or resistance biology.
- Proteomics/core facility scientists & method developers implementing high-throughput plasma assays for large clinical cohorts.
- Biostatisticians/data scientists analyzing proteomic + clinical data for biomarker validation and patient stratification in trials.
If you cannot attend this webinar please register to receive a link to the On Demand version the following day.
Presenter: Yu-Ju Chen Ph.D. (Professor, Academia Sinica, Taiwan)
Presenter: Stefani Thomas Ph.D. (Assistant Professor, University of Minnesota)
Presenter: Jessica Moore Ph.D. (Senior Scientist, Discovery Life Sciences)
